• News Desk

China leads COVID-19 vaccine race "at war time speed"


Bottle Labled Vaccine

SEOUL/SINGAPORE (Reuters) - China is forging ahead in the race to develop a vaccine to help control the COVID-19 pandemic, with Sinovac Biotech’s (SVA.O) experimental vaccine set to become the country’s second and the world’s third to enter final stage testing later this month.

While a laggard in the global vaccine industry, China, where the new coronavirus is thought to have originated, has brought state, military and private sectors together in a quest to combat a disease that has killed over 500,000 people worldwide.


Many other countries, including the United States, are coordinating closely with the private sector to try to win the vaccine development race, and China faces many challenges.

Its success in driving down COVID-19 infections makes it harder to conduct large-scale vaccine trials, and so far only a few other countries have agreed to work with it. After past vaccine scandals, Beijing will also have to convince the world it has met all safety and quality requirements.


But China’s use of command economy-type tools is so far yielding results. A state-controlled entity, for example, completed two vaccine plants at what it called the “war time speed” of a couple of months, while state-owned enterprises and the military have allowed experimental shots to be used on staff.

The People’s Liberation Army’s (PLA) medical research unit, which has been a driving force in China’s efforts to fight infectious diseases, is also working with private firms including CanSino (6185.HK) to develop COVID-19 vaccines.

ADVERTISEMENT

Challenging the West’s traditional dominance of the industry, China is behind eight of the 19 vaccine candidates in human trials, with Sinovac’s experimental shot and one jointly developed by the military and CanSino among the front runners.


It is also focused mainly on inactivated vaccine technology - a technology that is well known and has been used to make vaccines against diseases such as influenza and measles - something which could raise the chances of success.


By contrast, several Western rivals such as U.S.-based Moderna (MRNA.O) and Germany’s CureVac and BioNTech (BNTX.O) are using a new technology called messenger RNA that has never before yielded a product approved by regulators.


Read More...

amazon smile for pragnya.png
Our Non- Profit Partners
pragnya_logo.png
LOCAL EVENTS
BUSINESS NEWS
INDIA NEWS
BAY AREA NEWS

Powered by Studio M | 1917 Concourse Dr. San Jose CA 95131

  • Mediamahima